

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Bayer acquires Icon Genetics AG

Leverkusen / January 11, 2006 – Bayer Innovation GmbH (BIG), a subsidiary of the Bayer Group engaged in developing new fields of business, has acquired Icon Genetics AG, a biotech company headquartered in Munich, Germany. Icon Genetics discovers innovative methods for the development and use of engineered plants. Bayer and Icon Genetics are already cooperating on research.

The acquisition will strengthen Bayer's activities aimed at producing specific pharmaceutical substances in plants (plant-made pharmaceuticals, or PMPs). This technology utilizes the natural protein production processes in plants as a way of producing therapeutically active substances. The parties have agreed not to disclose any details of the acquisition. Closing of the transaction took place on January 9, 2006.

Icon Genetics, established in 1999 and financed by venture capital from IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, CFH GmbH, KfW-Bankengruppe and BioM AG, has sites in Halle and Munich. The company is engaged in developing processes for the biotechnological production of biopharmaceuticals and other high-value products in plants. The results of this activity are reflected in a total of more than 40 patents granted or applied for.

Bayer Innovation GmbH (BIG), headquartered in Düsseldorf, is a wholly owned subsidiary of Bayer AG. BIG evaluates and develops new fields of business for the Bayer Group that are in line with Bayer's core competencies of health care, nutrition and high-tech materials and complement its current key areas of innovation and business.

Leverkusen, January 11, 2006

Bayer AG. Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ilia Kürten (+49-214-30-35426)


Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Product Perfectly Complements Bayer's Hematology and Cardiology Portfolio:

Bayer HealthCare and Nuvelo Enter Into Collaboration Agreement for Global Development and Commercialization of Alfimeprase

- Bayer HealthCare To Commercialize in All Territories Outside the U.S.
 - Nuvelo Retains U.S. Commercialization Rights and Will Receive Milestone Payments of up to \$385 million
-

Leverkusen / January 5, 2006 – Bayer HealthCare (BHC) today announced that it has entered into a collaboration agreement with Nuvelo Inc. (Nasdaq: NUVO) for the global development and commercialization of a novel thrombolytic or blood clot dissolver which is currently in clinical phase III development. The compound, alfimeprase, directly degrades fibrin and has been shown in clinical studies to provide rapid clot dissolution.

"This phase III compound has the potential to be a significant addition to our cardiology/hematology business," said Wolfgang Plischke, President of Bayer HealthCare's Pharmaceutical Division. "Thrombosis-related diseases are highly prevalent, and alfimeprase's ability to rapidly dissolve clots in clinical trials conducted to date suggest it may be the ideal complement to our range of products that address coagulation and thrombosis. We believe alfimeprase has the potential to transform the treatment of patients suffering from thrombotic-related disorders."

Because of the late-stage development status of alfimeprase, Nuvelo is eligible to receive up to \$385 million in milestone payments including a \$50 million up-front cash payment. Bayer HealthCare will be responsible for 40 percent of the costs for global development programs. Nuvelo will be responsible for 60 percent of the costs and will retain the lead for the design and conduct of the global development

programs. Bayer HealthCare will commercialize alfineprase in all territories outside the United States and will pay Nuvelo sales-dependent tiered royalties ranging up from 15.0 percent to 37.5 percent. Under the terms of the agreement, Nuvelo will retain commercialization rights in the United States.

“In 2005 we articulated our strategy to pursue a partnership for alfineprase that would maximize its commercial potential and allow us to accelerate commercialization outside of the U.S. while establishing our own domestic sales force,” said Ted W. Love, M.D., chairman and chief executive officer of Nuvelo. “Bayer HealthCare proved to be the optimal partner based on its cardiovascular development and commercialization expertise, global reach and ability to provide significant resources to rapidly develop alfineprase’s full commercial potential.”

Alfineprase is an enzyme produced by recombinant DNA technology that rapidly dissolves blood clots through a unique mechanism of action by directly degrading fibrin, a protein that provides the scaffolding for blood clots. The product is currently being studied in phase III clinical trials for the potential treatment of acute peripheral arterial occlusion (PAO) and catheter occlusion (CO), and may have utility in a wide range of additional thrombotic-related conditions such as stroke, deep venous thrombosis (DVT) and myocardial infarction. These disorders are among the most common causes of death and morbidity in the Western world. The companies plan to expand beyond the current phase III programs and initiate additional clinical programs with alfineprase in stroke and DVT.

About Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry based in Leverkusen/Germany. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro. Bayer HealthCare employed 35,300 people worldwide in 2004.

The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units:

Hematology/Cardiology, Oncology and Primary Care. Bayer HealthCare’s aim is to discover and manufacture innovative products that will improve human and animal

health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's clinical pipeline includes alfimeprase, a direct-acting thrombolytic in phase III trials for the treatment of thrombotic-related disorders, and rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor complex that is currently in phase II clinical development for acute coronary syndromes. Nuvelo is also progressing preclinical development candidate, NU206, for the potential treatment of chemotherapy/radiation therapy-induced mucositis from its proprietary research programs. Nuvelo expects to leverage its expertise in secreted proteins and antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Leverkusen, January 5, 2006

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ilia Kürten (+49-214-30-35426)


Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Strategic fit for Bayer's pharma business:

Bayer HealthCare purchases Pritor business from GlaxoSmithKline

- Annual turnover of approximately EUR 65 million in Europe
 - Innovative medication for the treatment of high blood pressure
-

Leverkusen / January 3, 2006 - Bayer HealthCare (BHC) has purchased the European business for Boehringer Ingelheim's blood pressure treatment telmisartan (Pritor[®] and PritorPlus[®]) from GlaxoSmithKline plc (GSK) with an annual turnover of approximately EUR 65 million in 2005.

Telmisartan, an angiotensin II receptor blocker (ARB), is a long-acting anti-hypertensive treatment that provides powerful 24 hour blood pressure control. It is effective, has a favourable safety profile, and provides blood pressure protection, even in the risky early morning hours where the risk of myocardial infarction and stroke is at its highest. With a growth rate of about 15 percent ARBs, are the fastest growing and the most competitive segment in the European hypertension market. Pritor is therefore considered an attractive investment within this group.

With this acquisition BHC will gain the right to market the drug in Italy, Spain, France, Greece, Portugal and 22 smaller European markets. The companies agreed not to disclose the financial terms of the transaction.

"The acquisition of Pritor provides an excellent strategic fit for Bayer HealthCare's pharma business. The transaction allows us to utilize our excellent market knowledge and experience with the product in already existing Telmisartan markets," said Wolfgang Plischke, President of Bayer HealthCare's Pharmaceuticals Division.

Therewith BHC expands the number of markets in which it sells the product. Bayer HealthCare has had a co-marketing agreement with Boehringer Ingelheim/Germany, since 2002. Under that agreement BHC promotes telmisartan under the brand name Kinzalmono[®] and Kinzalkomb[®] in markets across Europe including Germany, Belgium, the Netherlands, Switzerland and Finland.

Telmisartan was discovered and developed by Boehringer Ingelheim who markets the compound under the trademark Micardis[®] in 84 countries around the world, including the USA, Japan and European countries. GlaxoSmithKline will continue to promote telmisartan as Pritor[®] under a co-marketing agreement with Boehringer Ingelheim in five countries.

Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro. Bayer HealthCare employed 35,300 people worldwide in 2004.


The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units: Hematology/Cardiology, Oncology and Primary Care.

Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

New treatment for advanced renal cell carcinoma:

Anticancer drug Nexavar[®] granted U.S. approval

- Approval faster than expected
 - Major milestone for Bayer oncology franchise
 - Shipment to pharmacies within the next 24 hours
-

Leverkusen / December 20, 2005 – Bayer HealthCare AG announced today that the U.S. Food and Drug Administration (FDA) has approved Nexavar[®] (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer. Nexavar is co-developed by Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. and has been shown to double progression free survival in patients with advanced RCC. It is the first FDA-approved treatment for this type of cancer in more than a decade. The companies expect that Nexavar will be shipped, primarily to specialty pharmacies, and available to patients within the next 24 hours.

“The FDA approval of Nexavar is a crucial step for patients with advanced kidney cancer therapy. We are delighted that, thanks to the rapid granting of approval, we will now be able to make this urgently needed product available earlier than planned,” said Werner Wenning, Chairman of the Board of Management of Bayer AG. “This also marks a great success for the realignment of our pharmaceuticals business and a major accomplishment in the commercial realization of the company’s oncology franchise.”

The FDA approved Nexavar based on data from the largest ever randomized, placebo-controlled, international trial in patients with advanced renal cell carcinoma, in which 130 centers participated. Treatment with Nexavar resulted in approximately a doubling of progression-free-survival.

“This approval is just the start of Nexavar’s life cycle. We are thankful to all of the RCC investigators and patients that have been involved, and are hopeful that Nexavar

will become a promising therapeutic option for other malignant tumors as well," said Arthur Higgins, chairman of Bayer HealthCare's executive committee. "In addition to Nexavar, we have other promising oncology compounds in various stages of development. Oncology is a priority development area for Bayer, and we will continue to invest aggressively and selectively in the most powerful and promising compounds."

Bayer HealthCare has also filed for regulatory approval with the European Medicines Evaluation Agency (EMA), where drugs can be granted marketing authorization for all EU countries through a centralized procedure. Pending a favourable review market availability is possible in the EU countries in late 2006. In addition, filings have been completed in Switzerland, Australia, Brazil, Canada and Mexico.

New Treatment Paradigms, Improved Outcomes

Innovations in cancer research and development are moving towards treating the disease chronically and through personalized medicine. With the approval of Nexavar, Bayer is at the leading edge of developments that may ultimately change the way we approach and manage diseases such as cancer.

Today's newer, targeted anti-cancer therapies are attacking tumors by arresting their growth: cutting off growth signals, stopping new blood supply, or both. Often times, these cytostatic therapies do not have the high level of toxicity associated with older, cytotoxic drugs, and, therefore, may be more tolerable and sustainable for patients to take over a longer period of time.

"Nexavar is one of a new breed of cancer therapies," said Dr. Wolfgang Plischke, Head of Bayer HealthCare's Pharmaceuticals Division. "Bringing us closer to the day when oncologists will have a war chest of effective, highly tolerable, and very combinable cancer treatments that may more closely resemble the long-term, 'drug-cocktail' regimens associated with other serious diseases like diabetes or even HIV."

"This is an exciting time in oncology-targeted therapies, in combination with current treatment and diagnostics, will help us find the right therapies for specific tumors and help us prolong life," said Plischke. "At Bayer, we're committed to being a major part of that excitement and will continue to invest heavily in the promising compounds and diagnostic testing in our pipeline."

About Nexavar

Nexavar is the first, oral multi-kinase inhibitor that targets serine/threonine and receptor tyrosine kinases in both the tumor cell and tumor vasculature. In preclinical models, Nexavar targeted members of two classes of kinases known to be involved in both

tumor cell proliferation (tumor growth) and tumor angiogenesis (tumor blood supply) - two important cancer growth activities. These kinases included RAF kinase, VEGFR-2, VEGFR-3, PDGFR- β , KIT, and FLT-3.

Nexavar has been studied in more than 20 tumor types and in more than 4,000 patients to date. It is currently in Phase III clinical trials for the treatment of advanced hepatocellular carcinoma (HCC), or liver cancer, and metastatic melanoma, or skin cancer. A Phase III clinical trial in non-small cell lung cancer (NSCLC) is planned for the first half of 2006.

About Bayer HealthCare AG

Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately EUR 8.5 billion in 2004, is one of the world's leading, innovative companies in the health care and medical products industry.

The company combines the global activities of the Animal Health, Biological Products, Consumer Care, Diagnostics, Diabetes Care and Pharmaceuticals divisions. 35,300 people were employed by Bayer HealthCare worldwide in 2004.

Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Leverkusen, December 20, 2005

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ilia Kürten (+49-214-30-35426)

Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.